Vanda Pharmaceuticals (NASDAQ:VNDA) Announces Earnings Results

Vanda Pharmaceuticals (NASDAQ:VNDA) announced its earnings results on Wednesday. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.46), FiscalAI reports. The firm had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 109.99% and a negative return on equity of 32.26%.

Here are the key takeaways from Vanda Pharmaceuticals’ conference call:

• Fanapt continued strong growth: Second-quarter prescriptions rose 31% year over year and net product sales increased 23% to $36.0 million, supported by the bipolar I disorder launch and an expanded sales force.
• Multiple pipeline and commercial catalysts are approaching: BYSANTI is expected to launch in the second half of 2026, Quimilza has a December 2026 FDA action date, and late-stage readouts for NEREUS, VQW-765, and HETLIOZ are expected by year-end.
• Profitability and cash usage deteriorated: Second-quarter net loss widened to $62.5 million from $27.2 million a year earlier, while operating expenses rose 25% to $114.3 million; management expects 2026 cash burn to exceed 2025 levels.
• HETLIOZ sales remain pressured by generic competition: Second-quarter revenue fell 66% to $5.6 million, although approximately $7 million of shipments delayed until July will be recognized in the third quarter.
• NEREUS launch results remain difficult to assess: The product generated $1.0 million in recognized sales, while $12.6 million of wholesaler-related revenue was constrained because of uncertainty around patient demand and potential returns from elevated inventory levels.

Vanda Pharmaceuticals Trading Down 4.5%

NASDAQ:VNDA traded down $0.24 during midday trading on Wednesday, hitting $5.09. The stock had a trading volume of 1,592,959 shares, compared to its average volume of 1,682,651. The company has a quick ratio of 2.15, a current ratio of 2.16 and a debt-to-equity ratio of 0.01. Vanda Pharmaceuticals has a one year low of $4.14 and a one year high of $9.94. The stock has a 50-day moving average of $5.84 and a 200 day moving average of $6.78. The company has a market capitalization of $306.06 million, a price-to-earnings ratio of -1.26 and a beta of 0.64.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on VNDA. Weiss Ratings reissued a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research report on Friday, July 17th. Wall Street Zen lowered Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Finally, HC Wainwright reiterated a “buy” rating on shares of Vanda Pharmaceuticals in a report on Thursday, June 4th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Vanda Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $14.30.

Institutional Trading of Vanda Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of VNDA. Russell Investments Group Ltd. lifted its position in Vanda Pharmaceuticals by 456.6% during the third quarter. Russell Investments Group Ltd. now owns 6,495 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 5,328 shares during the last quarter. Jain Global LLC acquired a new stake in Vanda Pharmaceuticals in the 4th quarter worth approximately $94,000. Quarry LP acquired a new stake in Vanda Pharmaceuticals during the 3rd quarter worth about $53,000. Boothbay Fund Management LLC purchased a new stake in shares of Vanda Pharmaceuticals in the 3rd quarter valued at $72,000. Finally, Cerity Partners LLC acquired a new position in Vanda Pharmaceuticals during the second quarter valued at $69,000. Institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders and rare diseases. The company’s research and development efforts center on sleep-wake regulation, mood disorders, and movement disorders. Vanda’s mission is to address unmet medical needs by advancing novel molecules through clinical trials and regulatory review.

Vanda’s flagship commercial product is Hetlioz (tasimelteon), a melatonin receptor agonist approved by the U.S.